Test drug combinations for EGFR- and MET-changed lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced NSCLC with a specific “sensitizing” EGFR mutation and confirmed MET amplification
- Your cancer has progressed after osimertinib (with or without other medicines), and you must be able to provide new tissue or blood testing after that progression
- You must have scan evidence of cancer that can be measured by CT/MRI, or non-measurable disease that’s still documented on scans
- You need a brain scan (CT with contrast or MRI) and, if you have brain symptoms from metastases, they must be stable for at least 5 days on the same or lower steroid dose
- Your general health and lab tests must be within study limits (blood counts, liver and kidney labs, heart rhythm, and urine protein level)
- You must be able to swallow tablets whole and agree to blood sample tests for ctDNA (and allow sample “banking”)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
This trial tests a combination of three targeted drugs for people with advanced non-small cell lung cancer that has a specific EGFR gene change. The goal is to see if the combination can control the cancer when previous treatments have stopped working.
This study tests a new treatment for advanced non-small cell lung cancer that has stopped responding to targeted therapy and chemotherapy. The goal is to find a treatment that works better for people whose cancer has certain genetic changes.
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
This trial tests a combination of two targeted drugs (Glumetinib and Osimertinib) against standard chemotherapy for people with non-small cell lung cancer that has stopped responding to initial targeted therapy. It may be an option if your tumor has a specific genetic change called MET amplification or overexpression.
This trial tests a new combination of two targeted drugs, glumetinib and osimertinib, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination can help control the cancer better than standard treatments.
Hear when a new Recurrent Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.